April Biobullets

“I can't change the direction of the wind, but I can adjust my sails to always reach my destination.” -Jimmy Dean

• We’re inundated with new companies looking for investment applying AI to the biotech sector. While we are very bullish on the development of AI in biotech it is early days, but a lot of investment and activity is occurring applying new AI technology to drug discovery and we expect that pipeline to grown 10X in the coming years.

• The arsenal researchers and clinicians have to combat cancer continues to grow with an exciting new discovery at Sloan Kettering.

• The Russian invasion of Ukraine is causing all sorts of disruptions for pharma and biotech. If we live In a multi-polar world how will the biotech sector be impacted and what implications will this have for companies discovering and developing new therapies?

• Cochlear adds a bolt-on from Danish company Demant. Demant’s Oticon business does $75-80m per year of revenue, is loss-making at ($16.5m loss last year), and used in over 70,000 patients currently. The deal is Can cochlear turn this M&A activity into incremental profit for the group?

• The world of tokens and DAO’s has reached the frontier of biotech.